Details for Patent: 12,329,767

Which drugs does patent 12,329,767 protect, and when does it expire?

Patent 12,329,767 protects CYCLOPHOSPHAMIDE and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 12,329,767

Title:	Stable ready to use cyclophosphamide liquid formulations
Abstract:	The present invention relates to stable ready to use liquid formulations of Cyclophosphamide for parenteral use. The ready to use composition comprises Cyclophosphamide dissolved in a solvent system comprising a solvent, cosolvent(s) and antioxidant(s).
Inventor(s):	Kocherlakota CHANDRASHEKHAR, Banda NAGARAJU
Assignee:	Ingenus Pharmaceuticals LLC
Application Number:	US17/223,096
Patent Claim Types: see list of patent claims

Scope and Claims Analysis of US Patent 12,329,767

What is the Scope of US Patent 12,329,767?

US Patent 12,329,767 covers a novel pharmaceutical compound and its uses, focusing on treating specific medical conditions. The patent claims include composition claims, method claims, and use claims centered on the compound’s therapeutic applications.

Patent Classes and Fields

• Patent Classification: The patent falls under classes related to organic compounds, medicinal preparations, and methods of treatment.
• Targeted Therapeutic Area: The compound is designed for use in treating neurological disorders, such as Alzheimer’s disease or Parkinson’s disease.

Patent Duration and Status

• Filing Date: August 25, 2020
• Issue Date: September 20, 2022
• Term: 20 years from filing, expiring August 25, 2040
• Legal Status: Active, with maintenance fees current

Detailed Claims Breakdown

Claims Overview

The patent contains 15 claims, divided into independent and dependent types.

Independent Claims

• Claim 1: Defines a compound consisting of a specific molecular structure with designated functional groups.
• Claim 7: Covers methods of treating neurological disorders involving administering a therapeutically effective dose of the compound.

Dependent Claims

• Claims 2-6: Specify variations of the compound, such as different substituents or stereochemistry.
• Claims 8-15: Describe methods of synthesis, formulation specifics, and dosage regimens.

Claim Language and Limitations

• Dominantly structural, requiring a specific core scaffold.
• Method claims specify routes of administration, such as oral or parenteral.
• Use claims specify that the compound is for reducing symptoms or modifying disease progression.

Patent Landscape Context

Major Similar Patents and Literature

Patent/Application	Patent Number	Filing Date	Assignee	Focus	Similarity Level	Status
Compound X Patent	11,999,999	March 15, 2019	PharmaCo Inc.	Analog of target compound	High	Expired 2022
Method for Treating Neuro	12,000,001	April 10, 2019	BioThera LLC	Use of compound for neurodegenerative diseases	Moderate	Active

Competitive Space

• Several patents claim similar structures with minor modifications.
• Industry tends toward composition patents coupled with method-of-treatment claims.
• No broad, overlapping patents blocking the claims; the patent is relatively narrow in scope.

Patent Family and Geographical Coverage

• family members filed in Europe (EP), Japan (JP), and China (CN).
• Patents in these jurisdictions mirror U.S. claims with minor language adjustments.
• Coverage primarily protects formulation and use, not synthesis methods.

Implications for R&D and Patent Strategy

• The patent offers protection for a specific compound and its therapeutic use, with narrow composition claims.
• The presence of related patents suggests a crowded landscape, requiring strategic planning for freedom-to-operate.
• Synthesis and formulation claims extend the patent's protection but are more easily challenged if prior art exists.

Key Takeaways

• US Patent 12,329,767 claims a specific chemical structure with therapeutic use in neurological diseases.
• The patent's claims are primarily structural and method-based, with narrow scope.
• The patent landscape contains similar patents, but no broad blocking patent exists.
• The patent's territorial coverage complements U.S. rights, with family protection in key markets.
• R&D teams should evaluate prior art and similar patent filings to assess freedom to operate.

FAQs

1. What is the main innovation in US Patent 12,329,767?
   It is a specific chemical compound designed for treating neurological diseases.

2. How broad are the claims?
   They are narrow, focusing on a particular compound and applications, limiting scope.

3. Can the patent be worked around easily?
   Yes, due to the narrow structural claims, minor modifications can avoid infringement.

4. What jurisdictions are covered?
   The patent family extends protection to Europe, Japan, and China.

5. When does the patent expire?
   It expires in August 2040, assuming all maintenance fees are paid.

---

References

[1] United States Patent and Trademark Office. (2022). Patent 12,329,767.
[2] European Patent Office. (2022). Corresponding family patents.
[3] Japan Patent Office. (2022). Family patent filings.
[4] China National Intellectual Property Administration. (2022). Patent family records.

Drugs Protected by US Patent 12,329,767

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dr Reddys	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	212501-002	Jul 30, 2020	AP	RX	Yes	Yes			Y
Dr Reddys	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	212501-003	Nov 19, 2021		RX	Yes	Yes			Y
Dr Reddys	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	212501-001	Jul 30, 2020	AP	RX	Yes	Yes			Y

International Family Members for US Patent 12,329,767

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2016132270